OIG Advisory Opinion 26-10 Signals Scrutiny of Royalty-Based HCP Consulting Arrangements

The U.S. Department of Health and Human Services Office of Inspector General (OIG) has issued an unfavorable advisory opinion regarding a medical product company’s proposed royalty-based consulting arrangement with healthcare providers. The decision highlights significant fraud and abuse concerns under the federal Anti-Kickback Statute when compensation for advisory services is tied directly to product sales. For the consulting and advisory sector, particularly those serving the life sciences industry, this ruling underscores the need for rigorous compliance reviews of performance-based compensation models.

In May 2026, the U.S. Department of Health and Human Services Office of Inspector General (OIG) released Advisory Opinion 26-10, which scrutinized a medical product company’s proposal to engage healthcare provider (HCP) consultants. As reported by Lisa Damhof of Gardner Law, the proposed arrangement involved a broad range of advisory services, including training, proctoring, clinical feedback, and consulting on strategic initiatives across the company’s product line. The OIG ultimately issued an unfavorable opinion, concluding that the structure presented significant fraud and abuse concerns under the federal Anti-Kickback Statute (AKS) because it linked financial rewards to the volume or value of business generated by the consultants.

The core of the OIG’s concern centered on the arrangement’s two-tiered compensation model, which was based on performance evaluations conducted by a panel created by the requestor. HCP consultants who did not meet specific performance thresholds were to be paid an hourly fair market value (FMV) rate. However, those who met the thresholds would receive quarterly royalty payments tied to a specified percentage of product-line sales. The OIG noted that while royalty-based compensation is not inherently problematic, it becomes a regulatory risk when the consultants are in a position to influence the sales of the very products for which they are receiving royalties.

This ruling clarifies that the proposed arrangement failed to satisfy the safe harbor for personal services, management contracts, and outcomes-based payment arrangements. The OIG’s decision follows Advisory Opinion 25-11, which similarly emphasized the importance of structure, transparency, and documented AKS risk analysis in healthcare financial arrangements. For the consulting and advisory market, this signals a period of increased regulatory scrutiny regarding how experts are compensated, necessitating a move away from sales-contingent royalties toward more traditional FMV models to ensure compliance with federal law.